secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001558370-25-002978
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dogwood Therapeutics prices $4.8M registered direct offering; funds operations through Q1 2026
--------------------------------------------------------------------------------

- Sold 578,950 shares at $8.26 each for gross proceeds of approximately $4.8 million.
- Proceeds to advance Halneuron clinical development and for working capital.
- Offering closed March 14, 2025; Maxim Group LLC acted as sole placement agent.
- Company expects cash runway through Q1 2026; Halneuron Phase 2b CINP interim data planned for Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/0001558370-25-002978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837025002978/dwtx-20250312x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-002978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer